Use of VEGF inhibitors for tumor regression

Details for Australian Patent Application No. 2004247095 (hide)

Owner Regeneron Pharmaceuticals, Inc. The Trustees of Columbia University in the City of New York

Inventors Kandel, Jessica; Yamashiro, Darrell; Yancopoulos, George; Huang, Jianzhong; Holash, Jocelyn; Rudge, John

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004247095

PCT Pub. Number WO2004/110490

Priority 60/476,425 06.06.03 US

Filing date 4 June 2004

Wipo publication date 23 December 2004

International Classifications

A61K 045/00 Medicinal preparations containing active ingredients not provided for in groups

Event Publications

1 September 2005 PCT application entered the National Phase

  PCT publication WO2004/110490 Priority application(s): WO2004/110490

6 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004247096-Catastrophic disability bath

2004247089-Fluid treatment element